Page last updated: 2024-12-08
cositecan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cositecan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 148202 |
| CHEMBL ID | 1997373 |
| CHEBI ID | 177492 |
| SCHEMBL ID | 2315201 |
| MeSH ID | M0576755 |
Synonyms (42)
| Synonym |
|---|
| (19s)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
| CHEBI:177492 |
| cositecan |
| nsc-710270 |
| NCI60_038797 |
| karenitecin |
| 7-trimethylsilylethylcamptothecin |
| nsc710270 |
| cositecan (usan) |
| 203923-89-1 |
| D09327 |
| karenitecin (tn) |
| 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-, (4s)- |
| bnp1350 |
| unii-24r60nvc41 |
| (4s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h)-dione |
| 24r60nvc41 , |
| bnp-1350 |
| cositecan [usan:inn] |
| bnp 1350 |
| db 172 |
| DB05806 |
| cositecan [who-dd] |
| cositecan [mi] |
| 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy- 11-(2- (trimethylsilyl)ethyl)-, (4s)- |
| (4s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14h- pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h)-dione |
| cositecan [usan] |
| karentecin |
| cositecan [inn] |
| SCHEMBL2315201 |
| CHEMBL1997373 |
| DTXSID90174340 |
| HY-14812 |
| CS-0003573 |
| karenitecin (cositecan) |
| (s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione. |
| Q27095699 |
| POADTFBBIXOWFJ-VWLOTQADSA-N |
| cositecan;bnp 1350 |
| MS-28131 |
| 1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4s)- |
| AKOS040741401 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "Disappearance of the lactone form from the plasma was biexponential with a mean distribution half-life of 57." | ( Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Aleksic, A; Berg, SL; Blaney, SM; Dauser, R; Hausheer, F; Kerr, JZ; McGuffey, L; Nuchtern, JG; Thompson, PA, 2004) | 0.32 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " Future karenitecin clinical trials should include studies to monitor or evaluate the effects of these potential drug interactions on the overall toxicity of karenitecin when used in combination with other drugs." | ( Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. Hausheer, FH; Madden, T; Newman, RA; Smith, JA, 2003) | 0.32 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The novel camptothecin derivative BNP1350 (7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been developed for superior oral bioavailability and increased lactone stability." | ( Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH, 2002) | 0.31 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "0 mg/kg per dose via intraperitoneal injection for a period of 10 consecutive days, which is the dosage lethal to 10% of treated animals." | ( Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| pyranoindolizinoquinoline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (89.47) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.77) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (25.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 1 (5.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (65.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||